Q1 EPS Estimates for Sanara MedTech Lowered by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities researchers at HC Wainwright dropped their Q1 2026 EPS estimates for shares of Sanara MedTech in a research note issued on Thursday, April 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.04) for the quarter, down from their prior estimate of $0.13. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.06 EPS and FY2026 earnings at $0.16 EPS.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The company had revenue of $27.55 million during the quarter, compared to the consensus estimate of $27.90 million.

SMTI has been the subject of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Zacks Research downgraded shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sanara MedTech has a consensus rating of “Hold” and an average price target of $36.00.

Sanara MedTech Price Performance

Shares of Sanara MedTech stock opened at $16.83 on Tuesday. The company has a debt-to-equity ratio of 7.75, a current ratio of 1.80 and a quick ratio of 1.59. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95. The firm has a fifty day moving average price of $19.33 and a two-hundred day moving average price of $23.45. The company has a market cap of $154.33 million, a PE ratio of -3.98 and a beta of 1.10.

Hedge Funds Weigh In On Sanara MedTech

A number of hedge funds and other institutional investors have recently made changes to their positions in SMTI. Stonebridge Wealth Management LLC bought a new position in shares of Sanara MedTech during the 2nd quarter worth about $3,397,000. Royal Bank of Canada lifted its holdings in shares of Sanara MedTech by 127.3% during the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after acquiring an additional 65,887 shares during the period. Marshall Wace LLP lifted its holdings in shares of Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after acquiring an additional 42,237 shares during the period. Squarepoint Ops LLC lifted its holdings in shares of Sanara MedTech by 343.4% during the 3rd quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock worth $996,000 after acquiring an additional 24,305 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Sanara MedTech during the 4th quarter worth about $355,000. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.